Valuation: Orexo AB

Market Cap 513M 54.11M 46.86M 43.68M 40.18M 75.85M 5.14B 76.7M 201M 2.57B 203M 199M 8.53B P/E 2026 *
-1.4x
P/E 2027 * -2.02x
Enterprise Value 408M 43.04M 37.28M 34.75M 31.96M 60.34M 4.09B 61.01M 160M 2.05B 162M 158M 6.78B EV / Sales 2026 *
21.5x
EV / Sales 2027 * 13.5x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
Current month-2.31%
1 month-41.03%
3 months-26.28%
6 months-47.21%
Current year-52.29%
1 week 13.7
Extreme 13.7
15
1 month 13.7
Extreme 13.7
25.35
Current year 13.7
Extreme 13.7
36
1 year 13.7
Extreme 13.7
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap.
4/9/25 Buy

Chief Executive Officer

6 0.0000%
4/9/25 Free

Chief Executive Officer

1,393 0.0040%
3/9/25 Free 149 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-2.31%0.00%-29.95%-20.75% 53.78M
+0.76%-0.96%+59.82%+21.70% 316B
-0.92%-0.07%+34.38%-9.40% 73.28B
+0.34%+0.39%+37.49%+99.01% 9.87B
+0.10%-7.59%-4.29%-6.23% 8.15B
+2.76%+3.14%-14.67%-14.85% 4.38B
+0.40%+6.22%-33.30%+7.29% 3.91B
+2.46%+2.51%-14.87%+21.19% 3.62B
+8.16%+0.69%+24.94%+45.40% 2.51B
-0.19%+6.42%-2.77%-3.33% 2.24B
Average +1.16%-0.71%+5.68%+14.00% 42.42B
Weighted average by Cap. +0.52%-1.99%+50.86%+17.08%

Financials

2026 *2027 *
Net sales 19M 2M 1.73M 1.62M 1.49M 2.81M 190M 2.84M 7.46M 95.28M 7.52M 7.36M 316M 27.5M 2.9M 2.51M 2.34M 2.15M 4.06M 276M 4.11M 10.79M 138M 10.89M 10.65M 457M
Net income -375M -39.53M -34.23M -31.91M -29.35M -55.41M -3.76B -56.03M -147M -1.88B -148M -145M -6.23B -270M -28.51M -24.69M -23.02M -21.17M -39.97M -2.71B -40.41M -106M -1.36B -107M -105M -4.49B
Net Debt -105M -11.07M -9.59M -8.94M -8.22M -15.51M -1.05B -15.69M -41.21M -527M -41.57M -40.65M -1.74B -143M -15.07M -13.05M -12.17M -11.19M -21.13M -1.43B -21.37M -56.13M -717M -56.61M -55.36M -2.37B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
06/08/26 SEK 14.36 -2.31% 47,738
04/08/26 SEK 14.70 +1.52% 18,124
03/08/26 SEK 14.48 -1.50% 27,813
31/07/26 SEK 14.70 +0.68% 55,246
30/07/26 SEK 14.60 +1.67% 108,507
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise